Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Condition:   Plaque Psoriasis Interventions:   Drug: Humira (Adalimumab);   Drug: SB5 (Adalimumab Biosimilar) Sponsor:   Samsung Bioepis Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2022 Category: Research Source Type: clinical trials

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Condition:   Plaque Psoriasis Interventions:   Drug: Humira (Adalimumab);   Drug: SB5 (Adalimumab Biosimilar) Sponsors:   Samsung Bioepis Co., Ltd.;   Organon and Co Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2022 Category: Research Source Type: clinical trials

Immunoclassification of Psoriasis: a Strategy for Precision Medicine
Conditions:   Immunoclassification;   Psoriasis Intervention:   Biological: adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate Sponsor:   Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 17, 2022 Category: Research Source Type: clinical trials